Business
Further data from TutevaT validation study
Further data from TutevaT validation study.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n Verici Dx plc\n \n \n \n \n (\"Verici Dx\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Further data from Tuteva™ clinical validation study presented\n \n \n \n \n \n \n \n \n \n Performance in blinded multi-centre trial establishes new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022\n \n \n \n \n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n announces that the additional data from its blinded, international, multi-centre validation study for Tuteva™, the Company's post-transplant blood test focused on acute rejection, has been presented at theAmerican Transplant Congress (\"ATC\") earlier this month.\n \n \n \n \n \n The further data demonstrates a Positive Predictive Value (\"PPV\") of 60% and Negative Predictive Value (\"NPV\") of 80% for Tuteva™, a next-generation RNA sequencing assay. This and the ability to detect all types of rejection support improved clinical diagnosis compared to that currently available from other kidney transplant blood tests without enhancement from clinical features, and in a broad validation population. This data confirms that Tuteva™ demonstrates strong performance in the detection of acute rejection, following a kidney transplant. These clinically important results position Tuteva™ for an on-schedule commercial launch later this year to support the estimated c. 100,000 global patients who undergo kidney transplant procedures annually.\n \n \n \n \n \n The study design and successful outcomes were well received at ATC and the poster, presented at the Congress and referenced during the closing session of the \"What's new / What's hot\" roundup, is now available on the Company website here:\n \n https://vericidx.com/clinical\n \n \n \n \n \n \n Further details can be seen in the poster, but key conclusions from the study are outlined below:\n \n \n \n \n \n \n \n \n \n \n \n \n •\n \n \n \n \n \n \n Validation in an all-comers cohort1 that is independent of the training set and representing all forms and levels of rejection is essential to assessment of expected test performance in translational clinical care settings to support medical management decision making.\n \n \n \n \n \n \n \n \n \n \n 1\n \n \n \n ...